These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24462126)

  • 1. TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA.
    Pers YM; Cadart D; Rittore C; Ravel P; Daïen V; Fabre S; Jorgensen C; Touitou I
    Joint Bone Spine; 2014 Jul; 81(4):370-2. PubMed ID: 24462126
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
    Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
    Martínez-Estupiñán L; Hernández-Flórez D; Janta I; Ovalles-Bonilla JG; Nieto JC; González-Fernández CM; Del Río T; Monteagudo I; López-Longo FJ; Naredo E; Valor L
    Clin Exp Rheumatol; 2018; 36(1):88-93. PubMed ID: 28850020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis.
    Goëb V; Dieudé P; Vittecoq O; Mejjad O; Ménard JF; Thomas M; Gilbert D; Boumier P; Pouplin S; Daragon A; Fardellone P; Tron F; Cornélis F; Le Loët X
    Arthritis Res Ther; 2005; 7(5):R1056-62. PubMed ID: 16207322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents.
    Russell AS; Maksymowych WP; de Silva M
    Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study.
    Canet LM; Filipescu I; Cáliz R; Lupiañez CB; Canhão H; Escudero A; Segura-Catena J; Soto-Pino MJ; Ferrer MA; García A; Romani L; Pérez-Pampin E; González-Utrilla A; López Nevot MA; Collantes E; Fonseca JE; Sainz J
    Pharmacogenet Genomics; 2015 Jul; 25(7):323-33. PubMed ID: 25850964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism.
    Soto L; Sabugo F; Catalan D; Wurmann P; Cermenatti T; Gatica H; Aravena O; Salazar L; Aguillón JC; Cuchacovich M
    Clin Rheumatol; 2011 Mar; 30(3):391-5. PubMed ID: 21234628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
    Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis.
    Fisher BA; Plant D; Lundberg K; Charles P; Barton A; Venables PJ;
    J Rheumatol; 2012 May; 39(5):929-32. PubMed ID: 22467927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
    Bobbio-Pallavicini F; Caporali R; Bugatti S; Montecucco C
    J Rheumatol; 2008 Oct; 35(10):1903-5. PubMed ID: 18843754
    [No Abstract]   [Full Text] [Related]  

  • 12. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
    Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
    J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
    Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
    Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
    Onishi S; Yoshio T; Nagashima T; Minota S
    Mod Rheumatol; 2010 Oct; 20(5):528-30. PubMed ID: 20458607
    [No Abstract]   [Full Text] [Related]  

  • 16. Involvement of Tumor Necrosis Factor Receptor Type II in FoxP3 Stability and as a Marker of Treg Cells Specifically Expanded by Anti-Tumor Necrosis Factor Treatments in Rheumatoid Arthritis.
    Santinon F; Batignes M; Mebrek ML; Biton J; Clavel G; Hervé R; Lemeiter D; Breckler M; Busato F; Tost J; Ziol M; Boissier MC; Decker P; Semerano L; Bessis N
    Arthritis Rheumatol; 2020 Apr; 72(4):576-587. PubMed ID: 31609517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of HLA-DRB1 shared epitope, -308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis.
    Reneses S; González-Escribano MF; Fernández-Suárez A; Pestana L; Davila B; Wichmann I; García A
    J Rheumatol; 2009 Jun; 36(6):1143-9. PubMed ID: 19411391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.
    Dejaco C; Duftner C; Klotz W; Schirmer M; Herold M
    Scand J Rheumatol; 2009; 38(1):66-7. PubMed ID: 18759163
    [No Abstract]   [Full Text] [Related]  

  • 19. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
    BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.